4.7 Article

2D Covalent Organic Framework Direct Osteogenic Differentiation of Stem Cells

期刊

ADVANCED HEALTHCARE MATERIALS
卷 11, 期 10, 页码 -

出版社

WILEY
DOI: 10.1002/adhm.202101737

关键词

2D nanoparticles; covalent organic frameworks (COFs); drug delivery; tissue engineering

资金

  1. National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH) [DP2 EB026265]

向作者/读者索取更多资源

A new class of hydrolytically stable 2D COFs for sustained drug delivery to direct stem cell fate has been reported. Loading an osteogenic agent dexamethasone within the COFs enhances their osteoinductive ability, demonstrating their potential biomedical applications.
2D covalent organic frameworks (COFs) are an emerging class of crystalline porous organic polymers with a wide-range of potential applications. However, poor processability, aqueous instability, and low water dispersibility greatly limit their practical biomedical implementation. Herein, a new class of hydrolytically stable 2D COFs for sustained delivery of drugs to direct stem cell fate is reported. Specifically, a boronate-based COF (COF-5) is stabilized using amphiphilic polymer Pluronic F127 (PLU) to produce COF-PLU nanoparticles with thickness of approximate to 25 nm and diameter approximate to 200 nm. These nanoparticles are internalized via clathrin-mediated endocytosis and have high cytocompatibility (half-inhibitory concentration approximate to 1 mg mL(-1)). Interestingly, the 2D COFs induce osteogenic differentiation in human mesenchymal stem cells, which is unique. In addition, an osteogenic agent-dexamethasone-is able to be loaded within the porous structure of COFs for sustained delivery which further enhances the osteoinductive ability. These results demonstrate for the first time the fabrication of hydrolytically stable 2D COFs for sustained delivery of dexamethasone and demonstrate its osteoinductive characteristics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据